MedPath

the Efficacy and Safety of Blueberry Yeast Fermentation Freeze Dying Powder on Promotion of Immunity

Not Applicable
Completed
Conditions
Immunity
Interventions
Dietary Supplement: Blueberry Yeast Fermentation Freeze Dying Powder Extract
Dietary Supplement: Placebo
Registration Number
NCT03923894
Lead Sponsor
Chonbuk National University Hospital
Brief Summary

This study was conducted to investigated the effects of daily supplementation of Blueberry Yeast Fermentation Freeze Dying Powder on Promotion of Immunity.

Detailed Description

This study was a 8-week, randomized, double-blind, placebo-controlled human trial. 100 subjects were randomly divided into Blueberry Yeast Fermentation Freeze Dying Powder extract 2.07 g or placebo group. The investigated measured Natural Killer cell activity, Cytokines, Upper respiratory infection questionnaire score, etc.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Adult men and women over 50 years
  • After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice
Exclusion Criteria
  • If screening shows that the white blood cell(WBC) is less than 3000/㎕ or more than 8000/㎕

  • Those who received influenza vaccination within 3 months before the screening

  • Those who have a body mass index(BMI) of less than 18.5 kg / m2 or greater than 35 kg / m2 at the screening

  • Those who have a clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, liver biliary system, kidney and urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic

  • Those who take a medication or health function food that affects your promotion of immunity within 1 month prior to the screening

  • Those who have received antipsychotic medication within 3 months before screening

  • Those who alcoholic or drug abuse suspected

  • Those who participated in other clinical trials within 3 months before screening

  • Laboratory test by show the following results

    • Aspartate Transaminase(AST), Alanine Transaminase(ALT) > Reference range 3 times upper limit
    • Serum Creatinine > 2.0 mg/dL
  • Pregnancy or breast feeding

  • Those who doesn't accept the implementation of appropriate contraception of a childbearing woman

  • Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Blueberry Yeast Fermentation Freeze Dying Powder ExtractBlueberry Yeast Fermentation Freeze Dying Powder ExtractBlueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
PlaceboPlaceboPlacebo 2.07 g/day for 8 weeks.
Primary Outcome Measures
NameTimeMethod
Changes of Natural Killer cell activity8 week

Natural Killer cell activity was measured in study baseline and 8 week. A ratio of effector cell and target cell was 50:1, 25:1, 12.5:1.

(Experimental - Effector Spontaneous - Target Spontaneous) / (Target Maximum - Target Spontaneous) × 100

Secondary Outcome Measures
NameTimeMethod
Changes of Cytokines8 week

For blood Cytokines analysis, collect 3 ml of blood in one SST tube for 5 ml, leave at room temperature for 30 minutes for clotting, after then centrifuge at 3000 rpm (or 2000 xg) for 10 minutes.

Inspection item were IL-2, IL-6, IL-12, IFN-γ, TNF-α.

Changes of Upper respiratory infection questionnaire score8 week

The upper respiratory infection questionnaire will investigate the occurrence of symptoms of upper respiratory infections (or symptoms), the score by symptom, the duration (days), and survey on the day of visit (1st, 2nd and 3rd visits).

The questionnaire items were classified into three groups according to whether or not the symptoms of upper respiratory infections (or symptoms) occurrence (yes or no), the types of symptoms (sore throat, rhinorrhea, nasal obstruction, sneezing, hoarseness, myalgia, earache, fever, headache, cough, sputum, dyspnea, diarrhea, nausea, vomiting)and symptoms level (0 if no symptoms, 1 if slightly, 2 if normal, 3 severe).

Trial Locations

Locations (1)

Clinical Trial Center for Functional Foods Chonbuk National University Hospital

🇰🇷

Jeonju, Jeollabuk-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath